DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04920617 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: DPX-Survivac
DRUG: Pembrolizumab
DRUG: CPA

Sponsor

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Collaborators

[object Object]